Arcutis Submits Topical Roflumilast Foam 0.3% New Drug Application to the FDA for the Treatment of…
<!-- Name:DistributionId Value:8752161 -->
<!-- Name:EnableQuoteCarouselOnPnr Value:False -->
<!-- Name:IcbCode Value:4573 -->…
Browsing Tag
seb derm
New Data from Arcutis’ Topical Roflumilast Clinical Program Presented at the European Academy of…
WESTLAKE VILLAGE, Calif., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), an early-stage commercial company focused on developing meaningful innovations in immuno-dermatology, today announced that four…